Catabasis Pharma (CATB) Surges 50% on Deal with Serepta (SRPT)

September 29, 2016 9:47 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Catabasis Pharma (NASDAQ: CATB) is surging 49% in early trade after the company announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD) with Serepta Therapeutics, Inc. (Nasdaq: SRPT).

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment